Morphin Morphinsulfat Al (Morphine Sulfate)

Morphine sulfate, the active ingredient in Morphin Morphinsulfat Al, is an opioid analgesic presented as an oral formulation for systemic use. It is employed to manage severe pain conditions, including acute, post‑operative, and cancer‑related pain, in adult patients requiring strong analgesia.

GNH USA supplies Morphin Morphinsulfat Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, adhering to EU GMP standards and providing reliable global distribution. The company ensures batch consistency and regulatory compliance across all markets.

Morphine sulfate is an opioid analgesic used to treat pain conditions that involve the central nervous system.

Severe acute pain: delivers potent analgesia to quickly alleviate intense, short‑term pain episodes such as trauma or injury. Post‑operative pain: helps control moderate to severe pain following surgical interventions, facilitating patient comfort and recovery. Cancer‑related pain: provides sustained relief of chronic malignant pain, improving quality of life for oncology patients. These indications reflect the drug’s role in managing high‑intensity pain where alternative analgesics are insufficient.

Morphine sulfate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Constipation - Drowsiness - Dizziness - Vomiting

Serious or Rare Side Effects: - Respiratory depression - Hypotension - Severe allergic reaction (anaphylaxis) - Dependence or addiction - Adrenal insufficiency - Serotonin syndrome

When prescribing morphine sulfate, clinicians should observe several safety measures to minimize risks.

Assess pain severity and opioid tolerance: determine baseline pain and prior opioid exposure before initiating therapy. Monitor respiratory function: observe for signs of respiratory depression, especially during dose titration. Evaluate for concomitant CNS depressants: avoid or adjust dosing when combined with benzodiazepines or alcohol. Adjust dose in renal or hepatic impairment: reduce dosage or increase interval in patients with organ dysfunction. Educate patients on dependence risk: inform about signs of misuse and the need for proper disposal. Store below 25°C: keep in the original packaging, protect from moisture and light.

Morphine sulfate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Benzodiazepines and other CNS depressants: combined use may cause profound respiratory depression. - Monoamine oxidase inhibitors (MAOIs): concurrent use can precipitate severe hypertension or serotonin syndrome. - Other opioids: additive effects increase risk of overdose and respiratory compromise. - Potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): raise morphine plasma levels, heightening toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce morphine concentrations, diminishing analgesia. - Anticholinergic agents: can exacerbate constipation. - Diuretics: may enhance hypotensive effects. - Alcohol: increases sedation and respiratory depression risk. - Selective serotonin reuptake inhibitors (SSRIs): may increase risk of serotonin syndrome.